Arcturus outlines 12-week Phase II CF trial launch and expects regulatory clarity for ARCT-810 in 2026

Earnings Call Insights: Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2025

MANAGEMENT VIEW

* CEO Joseph Payne provided an update on the ARCT-032 and ARCT-810 programs, stating the ARCT-032 Phase II trial is progressing with higher dose testing at 15 milligrams in 4 Class I CF adults with no safety concerns. "We are well on track to initiate dosing for this Phase II 12-week study in the first half of this year and look forward to generating potentially meaningful clinical data for our CF program in 2026" (Founder, President, CEO & Director Joseph Payne).
* For ARCT-810, Payne reported plans to study both adults and young children, with regulatory meetings scheduled for the first half of 2026. "These meetings are intended to provide clarity regarding our next steps in clinical development for our flagship rare liver disease program" (Founder, President, CEO & Director Joseph Payne).
* The CEO announced U.K. approval for the partnered COVID-19 vaccine Costave in January 2026 for individuals aged 18 and older and noted continued progress and funding for the STAR vaccine candidate ARCT-2304 for A/H5N1 influenza, highlighting durable immune responses and tolerability.
* CFO remarks included: "Year-over-year, annual and quarterly revenue decreased $70.3 million and $15.6 million, respectively. These declines were driven by reductions in revenue from our CSL collaboration, reflecting lower supply agreement activity and a reduced number of development-based milestone achievements as Costave was commercialized. Annual and quarterly research and development expenses also decreased year-over-year by $83.0 million and $19.3 million, respectively, which was primarily driven by lower manufacturing and clinical costs related to the LUNAR-COV19 program" (Founder, President, CEO & Director Joseph Payne).
* Cash, cash equivalents and restricted cash were $232.8 million as of December 31, 2025.

OUTLOOK

* The company expects to initiate the 12-week Phase II ARCT-032 study in the first half of 2026, enrolling up to 20 participants and focusing on safety and early signs of clinical benefit.
* For ARCT-810, Type C regulatory meetings are scheduled for the first half of 2026 to align on pivotal trial designs for both adults and pediatric populations.
* Management stated, "We expect general and administrative expenses to continue to decrease during the next 12 months, driven by lower share-based compensation expense" (Founder, President, CEO & Director Joseph Payne).
* The cash runway is projected to extend into the second quarter of 2028.

FINANCIAL RESULTS

* Annual and quarterly revenue declined $70.3 million and $15.6 million year-over-year, respectively, due to lower CSL collaboration activity.
* Research and development expenses dropped by $83.0 million annually and $19.3 million quarterly, reflecting lower manufacturing and clinical costs as LUNAR-COV19 transitioned to a commercial phase.
* General and administrative expenses decreased annually by $6.7 million, but quarterly G&A increased $1.6 million due to accelerated employee stock options.
* Cash, cash equivalents and restricted cash stood at $232.8 million at year-end 2025.

Q&A

* Yasmeen Rahimi, Piper Sandler: Asked about study optimizations in the upcoming 12-week Phase II for ARCT-032 and patient enrollment support from the CF Foundation. CEO Payne and an executive described enhanced reproducibility and stability parameters, expanded endpoints, and close collaboration with the CF Foundation.
* Pete Stavropoulos, Cantor Fitzgerald: Inquired about the sensitivity and reliability of the LCI test and biomarker acceptance for the OTC program. Management explained LCI’s advantages and ongoing regulatory discussions, noting clarity is expected after Type C meetings.
* Seamus Fernandez, Guggenheim Securities: Sought clarification on dose selection for ARCT-032 and international recruitment. Payne indicated the 12-week cohort will start at 10 mg based on early efficacy, with flexibility to increase to 15 mg if needed. International sites were added to access more patients with relevant mutations.
* Lili Nsongo, Leerink Partners: Asked about dose escalation flexibility and pediatric regulatory strategy for OTC. Payne confirmed the ability to increase doses within the study and anticipated bifurcated regulatory paths for adults and children.
* Yanan Zhu, Wells Fargo: Probed stable baseline importance and regulatory outcomes for OTC. Management emphasized tighter enrollment criteria for baseline stability and the goal of regulatory clarity for both adults and pediatric populations in 2026.
* Adam Walsh, ROTH Capital: Queried extra exposure time in the 12-week CF study and functional data for ARCT-810. Payne remarked on the longer potential healing period and said pivotal planning would consider functional clinical data.
* Multiple analysts revisited dose selection, baseline stability, and regulatory alignment topics, with management consistently signaling flexibility and a focus on regulatory engagement.

SENTIMENT ANALYSIS

* Analysts pressed for clarity on dose selection, regulatory engagement, and specific endpoints. The tone was neutral to slightly positive, with recurring questions on study design and regulatory pathways.
* Management maintained a confident and measured tone, emphasizing flexibility and progress: "We feel confident in the dose that we've selected at 10 to start this fourth cohort" (Founder, President, CEO & Director Joseph Payne). Management’s tone was similarly confident in both prepared remarks and Q&A, versus the previous quarter where some responses showed more hesitation due to regulatory uncertainty.
* Compared to the prior quarter, both management and analysts exhibited increased focus on regulatory clarity and execution, with more confidence around the launch of the 12-week study.

QUARTER-OVER-QUARTER COMPARISON

* Guidance now includes a firm timeline for the 12-week ARCT-032 Phase II study launch in early 2026, while the previous quarter indicated planning was contingent on third cohort top-line data.
* Strategic focus has shifted from data collection in smaller cohorts to the execution of a larger, longer-duration study with enhanced endpoints.
* Analysts in both quarters emphasized dose selection, regulatory strategy, and trial design, but the current quarter featured more detailed discussions on operational execution and international expansion.
* Management’s confidence has increased, particularly around regulatory engagement and study design, reflecting progress from preparatory to operational phases.

RISKS AND CONCERNS

* Management highlighted ongoing litigation against AbbVie and Capstone Therapeutics.
* Lower revenues from the CSL collaboration were cited as a primary reason for overall revenue declines.
* There was mention of challenges in securing Costave licensure in the U.S. due to regulatory hurdles, leading to ongoing discussions with CSL regarding the collaboration’s future.
* Management acknowledged the complexity of enrolling stable CF patients and the potential for variable patient baselines, with strategies to mitigate these risks.

FINAL TAKEAWAY

The company is poised to initiate a pivotal 12-week Phase II study for ARCT-032 in cystic fibrosis during the first half of 2026, focusing on safety and clinical efficacy in a larger, multinational cohort. Regulatory clarity for ARCT-810 remains a key milestone, with Type C meetings scheduled for the first half of 2026 to determine the path forward for both adult and pediatric populations. Cost controls, reduced R&D and G&A expenses, and a robust cash position extending into 2028 support this strategic refocus on mRNA-based rare disease therapeutics and vaccines. Management underscores operational flexibility and ongoing regulatory engagement as central to achieving near-term value-creating milestones.

Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/arct/earnings/transcripts]

MORE ON ARCTURUS THERAPEUTICS

* Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2025 Earnings Call Transcript [https://seekingalpha.com/article/4878064-arcturus-therapeutics-holdings-inc-arct-q4-2025-earnings-call-transcript]
* Arcturus Therapeutics: Two Catalysts, One Runway, And A Stock Priced For Failure [https://seekingalpha.com/article/4869644-arcturus-therapeutics-two-catalysts-one-runway-and-a-stock-priced-for-failure]
* Seeking Alpha’s Quant Rating on Arcturus Therapeutics [https://seekingalpha.com/symbol/ARCT/ratings/quant-ratings]
* Historical earnings data for Arcturus Therapeutics [https://seekingalpha.com/symbol/ARCT/earnings]
* Financial information for Arcturus Therapeutics [https://seekingalpha.com/symbol/ARCT/income-statement]